Compare VENUS REMEDIES with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs BIOCON - Comparison Results

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES BIOCON VENUS REMEDIES/
BIOCON
 
P/E (TTM) x -1.1 22.8 - View Chart
P/BV x 0.1 3.0 2.5% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 VENUS REMEDIES   BIOCON
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
BIOCON
Mar-18
VENUS REMEDIES/
BIOCON
5-Yr Chart
Click to enlarge
High Rs1261,188 10.6%   
Low Rs61305 20.0%   
Sales per share (Unadj.) Rs301.868.7 439.1%  
Earnings per share (Unadj.) Rs-24.97.6 -329.3%  
Cash flow per share (Unadj.) Rs2.514.0 18.2%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs293.386.3 339.7%  
Shares outstanding (eoy) m12.34600.00 2.1%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.310.9 2.9%   
Avg P/E ratio x-3.898.9 -3.8%  
P/CF ratio (eoy) x36.753.4 68.8%  
Price / Book Value ratio x0.38.6 3.7%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m1,154447,900 0.3%   
No. of employees `0000.96.1 15.0%   
Total wages/salary Rs m3939,311 4.2%   
Avg. sales/employee Rs Th4,026.16,705.8 60.0%   
Avg. wages/employee Rs Th425.01,514.2 28.1%   
Avg. net profit/employee Rs Th-331.8736.9 -45.0%   
INCOME DATA
Net Sales Rs m3,72441,234 9.0%  
Other income Rs m232,062 1.1%   
Total revenues Rs m3,74743,296 8.7%   
Gross profit Rs m3958,291 4.8%  
Depreciation Rs m3383,851 8.8%   
Interest Rs m354615 57.6%   
Profit before tax Rs m-2755,887 -4.7%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m321,569 2.0%   
Profit after tax Rs m-3074,531 -6.8%  
Gross profit margin %10.620.1 52.7%  
Effective tax rate %-11.526.7 -43.1%   
Net profit margin %-8.211.0 -75.0%  
BALANCE SHEET DATA
Current assets Rs m2,63841,486 6.4%   
Current liabilities Rs m2,30521,413 10.8%   
Net working cap to sales %8.948.7 18.4%  
Current ratio x1.11.9 59.1%  
Inventory Days Days13564 211.7%  
Debtors Days Days4694 49.2%  
Net fixed assets Rs m4,87150,661 9.6%   
Share capital Rs m1233,000 4.1%   
"Free" reserves Rs m3,49648,808 7.2%   
Net worth Rs m3,61951,808 7.0%   
Long term debt Rs m1,37417,898 7.7%   
Total assets Rs m7,50999,897 7.5%  
Interest coverage x0.210.6 2.1%   
Debt to equity ratio x0.40.3 109.9%  
Sales to assets ratio x0.50.4 120.2%   
Return on assets %0.65.2 12.3%  
Return on equity %-8.58.7 -97.0%  
Return on capital %1.69.6 16.4%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m012,058 0.0%   
Fx outflow Rs m5177,348 7.0%   
Net fx Rs m-5174,710 -11.0%   
CASH FLOW
From Operations Rs m5146,621 7.8%  
From Investments Rs m-123-6,840 1.8%  
From Financial Activity Rs m-387-2,397 16.1%  
Net Cashflow Rs m4-2,612 -0.2%  

Share Holding

Indian Promoters % 32.9 40.4 81.3%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 0.2 8.4 2.1%  
FIIs % 0.6 10.7 5.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 19.9 333.7%  
Shareholders   20,121 109,995 18.3%  
Pledged promoter(s) holding % 36.4 0.0 90,900.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   SUN PHARMA  PROCTER & GAMBLE HEALTH  NOVARTIS  J.B.CHEMICALS  DR. REDDYS LAB  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 72 Points Lower; Capital Goods and Auto Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day marginally lower.

Related Views on News

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 18, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS